Home | Medical Need | R&D Programmes | Company | Collaborations | News |

News, Publications, Posters, and Patents
Vaara, M., 2018. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin. Medicinal Research Reviews. Click the link here.

Vaara, M. et al. 2017. Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis.
Journal of Antimicrobial Chemotherapy. Click the link here.

[October 3, 2017] Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform. See Spero’s Press Release.

[August 16, 2017] "Agents That Increase the Permeability of the Outer Membrane", a review by Professor Martti Vaara, cited more than 1,000 times. Click here.

Corbett, D. et al. 2017. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob Agents Chemother 61:e00200-17. Click the link here.

Pyles, R.B. et al., 2017. Polymyxin B cyclic lipopeptide derivatives NAB739 and NAB815 significantly reduce experimental UTI infections in diabetic mice. ASM Microbe 2017, Poster 53117

[May 30, 2017] Spero Therapeutics Presents New Data on Lead Potentiator Candidate SPR741 at ASM Microbe 2017. See Spero’s Press Release.

[March 30, 2017] Spero Therapeutics Receives $6.8 Million Award from CARB-X to work on a partner compound for SPR741. See Spero’s Press Release.

Vaara, M., T. Vaara, and J. Tyrrell. 2017. Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity. Peptides 91:8-12. Click the link here.

[March 8, 2017] Spero Therapeutics Secures $51.7 Million in Series C Financing. See Spero’s Press Release.

[December 19, 2016] SPR741 advances to Phase 1. See Spero’s Press Release.

[October 19, 2016] Spero Therapeutics Announces $1.65 Million Award from Department of Defense to Develop Novel Combination Therapy for Multidrug-Resistant, Gram-Negative Pathogens. See Spero’s Press Release.

[June 20, 2016] Spero Therapeutics Unveils Data on Lead Potentiator Candidate at ASM Microbe 2016. See Spero’s Press Release.

[February 2, 2016] Spero Therapeutics Announces $30 Million Series B Preferred Financing. See Spero’s Press Release as well as the FierceDrugDelivery report.

[September 17, 2015] Top team at Spero to work on the potentiators. See Spero’s Press Release.

[June 8, 2015] Northern Antibiotics has licensed its sensitizer compounds to Spero Therapeutics, Cambridge, Mass. Spero has now secured $30M million in a Series A financing, and intends to advance the franchise into clinical development by 2016. See Spero’s Press Release.

US Patent 8,680,234
US Patent 8,642,535
US Patent 8,329,645
US Patent 8,193,148
US Patent 7,807,637

Vaara, M. 2013. Novel derivatives of polymyxins. Journal of Antimicrobial Chemotherapy. Click the link here.

Vaara, M., T. Vaara. 2013. The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. International Journal of Antimicrobial Agents 41:292-293. Click the link here.

Vaara, M. et al., 2013. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. Journal of Antimicrobial Chemotherapy 68:636-639. Click the link here.

Mingeot-Leclercq et al., 2012. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 35:248-252. Click the link here.

Mingeot-Leclercq et al., 2011. Novel Polymyxin Derivatives are Less Cytotoxic than Polymyxin B in a model of LLC-PK1 Renal Cell Line.

Vaara, M. 2010. Polymyxins and their novel derivatives. Curr. Opin. Microbiol. 13:574-581.

Vaara, M., T. Vaara. 2010. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 31:2318-2321.

Vaara, M. et al. 2010. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 54:3341-3346.

Vingsbo Lundberg, C. et al. 2010. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J. Antimicrob. Chemother. 65:981-985.

Vaara, M., et al. 2010. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the polymyxin-like peptides NAB739 and NAB7061. J. Antimicrob. Chemother. 65:942-945.

Ali, F.E., G. Cao, A. Poydal, T. Vaara, R. L. Nation, M. Vaara, and J. Li. 2009. Pharmacokinetics of novel antimicrobial cationic peptides NAB7061 and NAB739 in rats following intravenous administration. J. Antimicrob. Chemother. 64:1067-1070.

Vaara, M., 2009. New approaches in peptide antibiotics. Curr. Opin. Pharmacol. 9:571-576.

Vaara, M. et al. 2008. Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents. Click the link here.

Vingsbo, C. et al., 2008. Novel Polymyxin Derivatives are Effective in Treating Peritoneal E.coli Infection in Mice.

Ali, F. et al., 2008. Pharmacokinetics (PK) of Novel Anti-Gram-negative (G-) Antibiotics in Rat.

  Northern Antibiotics Ltd
Tekniikantie 14 (Technopolis, Innopoli 2) Suite A111, FIN-02150 Espoo, Finland
Phone: +358-50-355 0822
E-mail: admin@northernantibiotics.com
  Copyright © 2007-2018 Northern Antibiotics Ltd